An act to add Section 1399.852 to the Health and Safety Code, and to add Section 10112.283 to the Insurance Code, relating to health care coverage.
SB 1199 would require California health care service plans and health insurers to count certain amounts paid toward a prescription drug as part of a patient’s cost sharing and out-of-pocket maximum calculations. In practical terms, when an enrollee or insured receives permitted manufacturer assistance or other qualifying direct support for a drug, that amount would generally have to be credited toward the person’s deductible, annual cost-sharing limit, and out-of-pocket maximum under the plan or policy. The bill applies to nongrandfathered plans and policies and excludes several categories, including grandfathered coverage, certain specialized plans, Medicare supplement coverage, and accident-only, specified disease, and hospital indemnity products.
The measure also creates an enforcement mechanism for health insurers through the Insurance Commissioner, including administrative penalties of up to $5,000 per violation, or up to $10,000 for willful violations. For health care service plans regulated under the Knox-Keene Act, a willful violation would remain a crime under existing law, which is why the bill is described as creating a state-mandated local program. The bill includes conforming language for high-deductible health plans tied to federal health savings account rules, so it does not undermine HSA eligibility where federal law would prohibit that result.
The bill’s impact on state law is to add new sections to both the Health and Safety Code and the Insurance Code governing how cost sharing is calculated for prescription drugs. It would effectively require insurers and plans to treat qualifying third-party or manufacturer assistance as if it were paid by the patient for purposes of reaching cost-sharing thresholds, subject to existing limits on manufacturer support in California law. This could reduce the amount of out-of-pocket spending some patients must make before their coverage begins paying at the highest level, while also limiting the ability of plans to exclude manufacturer assistance from those calculations.
Overall sentiment appears favorable in committee, with the bill passing the Assembly Appropriations Committee 9-0 and later moving on suspense file without recorded opposition in the provided history. The lack of dissent in the recorded votes suggests broad procedural support, at least at the committee level. At the same time, the bill’s placement on suspense indicates it may have been viewed as having fiscal or implementation implications significant enough to warrant further review.
The main points of contention likely center on the policy balance between lowering patient drug costs and preserving existing cost-sharing and manufacturer-assistance rules. Supporters would likely emphasize consumer affordability and improved access to medications, while opponents or cautious reviewers may be concerned about higher premium or plan costs, administrative complexity, and the interaction with federal HSA rules and existing prohibitions on certain manufacturer inducements. The bill text itself also preserves exceptions for certain manufacturer payments, which suggests lawmakers were trying to thread the needle between patient relief and anti-abuse safeguards.
SB 1199 would amend California insurance and managed care law by requiring health plans and health insurers to count qualifying prescription drug assistance toward enrollees’ and insureds’ deductibles, annual out-of-pocket limits, and other cost-sharing requirements. It adds Section 1399.852 to the Health and Safety Code and Section 10112.283 to the Insurance Code, applies to nongrandfathered coverage, and excludes several plan types. It also authorizes administrative penalties against insurers and preserves existing criminal enforcement for willful violations by health care service plans, while carving out HSA-qualified high-deductible plans where federal law would otherwise be affected.
The available vote history shows strong committee support, with a 9-0 do-pass vote as amended and no recorded opposition in the provided materials. The bill was later placed on the suspense file in Appropriations, suggesting fiscal scrutiny rather than policy opposition. No committee transcript was provided, so the overall sentiment can only be inferred from the unanimous committee vote and the bill’s continued movement through the process.
The likely policy dispute is whether manufacturer assistance should count toward a patient’s cost-sharing obligations. Supporters would view the bill as a consumer-protection and affordability measure that helps patients reach deductibles and out-of-pocket caps sooner. Potential critics may argue it could increase insurer or plan costs, complicate administration, or interact awkwardly with existing restrictions on drug manufacturer support and federal HSA rules. The bill addresses some of these concerns by excluding certain plan types and limiting application where federal law would be jeopardized.